viewSkinBioTherapeutics PLC

SkinBioTherapeutics preparing to kick off psoriasis study as it eyes a busy year

Financially, the group remains well placed. It finished the 12 months to June 30, 2020, with £2.2mln in the bank and topped this up last month with a further £4.45mln from a placing and open offer

SkinBioTherapeutics PLC -

SkinBioTherapeutics PLC (LON:SBTX) has said it is planning a 'self-managed' human study of its AxisBiotix programme targeting psoriasis in the first quarter of next year.

And, subject to a positive read-out, it expects to begin commercialising a product, investors were told in an update running alongside the firm’s full-year results.

The market will also be keenly tracking the progress of SkinBiotix, a cosmetic additive being developed under a deal the company has with FTSE 100 speciality chemicals and ingredients giant Croda International PLC (LON:CRDA). The launch of this new line is expected in 2022.

The prelims charted a period of significant progress for SkinBioTherapeutics, which has innovations targeting the ecosystem that exists on the skin and which is part of the human microbiome.

As well as the Croda deal, it also has an agreement with the Dutch firm Winclove Probiotics to develop a blend of 'good' bacteria strains to help manage the symptoms associated psoriasis. 

Financially, the group remains well placed for the year ahead. It finished the 12 months to June 30, 2020, with £2.2mln in the bank and topped this up last month with a further £4.45mln from a placing and open offer.

“The funding, aligned with the scientific and operational progress of the last 12 months, leaves the company ideally positioned to push forward with its strategy which offers exciting potential over the course of the next 24 months,” said chairman, Martin Hunt in the results statement.

In common with most companies at the formative stages of commercialisation, SkinBioTherapeutics was loss-making. The loss after tax was £1.62mln vs. £1.36mln the year earlier.

Quick facts: SkinBioTherapeutics PLC

Price: 39.1 GBX

Market: AIM
Market Cap: £60.95 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of SkinBioTherapeutics PLC named herein, including the promotion by the Company of SkinBioTherapeutics PLC in any Content on the Site, the Company...


Skinbiotherapeutics get set for live data trial to target skin conditions...

SkinBioTherapeutics PLC's (LON:SBTX) Stuart Ashman talks to Proactive London about their wholly-owned subsidiary AxisBiotix Limited which is getting ready for their food supplement consumer study. The study, which will accept around 200 applicants, the participants will be asked to take a...

on 14/1/21

2 min read